Discussion
Two drug developers are teaming up to advance toward clinical trials an inhaled treatment targeting the disease mechanisms underlying cystic fibrosis (CF). The U.S.-based Aptar Pharma and Aceso Therapeutics, headquartered in France, announced they will collaborate on developing ACT-101, an experimental RNA therapy. Unlike traditional drugs that target…